biperiden has been researched along with Psychotic Disorders in 21 studies
Biperiden: A muscarinic antagonist that has effects in both the central and peripheral nervous systems. It has been used in the treatment of arteriosclerotic, idiopathic, and postencephalitic parkinsonism. It has also been used to alleviate extrapyramidal symptoms induced by phenothiazine derivatives and reserpine.
biperiden : A member of the class of piperidines that is N-propylpiperidine in which the methyl hydrogens have been replaced by hydroxy, phenyl, and 5-norbornen-2-yl groups. A muscarinic antagonist affecting both the central and peripheral nervous systems, it is used in the treatment of all forms of Parkinson's disease.
Psychotic Disorders: Disorders in which there is a loss of ego boundaries or a gross impairment in reality testing with delusions or prominent hallucinations. (From DSM-IV, 1994)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Efficacy of ziprasidone (80-160 mg/d) and olanzapine 10-20 mg was measured using the Positive and Negative Syndrome Scale (PANSS), the Clinical Global Impression (CGI) Scale, the Calgary Depression Scale for Schizophrenia (CDSS), and the Heinrich Quality of Life Scale (HQLS); tolerability assessments included laboratory assessments, body weight, and electroencephalogram." | 9.15 | Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial. ( Buitelaar, JK; Grootens, KP; Kahn, RS; Peuskens, J; Sabbe, BG; Thys, E; van Veelen, NM; Verkes, RJ, 2011) |
| " Efficacy of ziprasidone (80-160 mg/d) and olanzapine 10-20 mg was measured using the Positive and Negative Syndrome Scale (PANSS), the Clinical Global Impression (CGI) Scale, the Calgary Depression Scale for Schizophrenia (CDSS), and the Heinrich Quality of Life Scale (HQLS); tolerability assessments included laboratory assessments, body weight, and electroencephalogram." | 5.15 | Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial. ( Buitelaar, JK; Grootens, KP; Kahn, RS; Peuskens, J; Sabbe, BG; Thys, E; van Veelen, NM; Verkes, RJ, 2011) |
| "Sixty-two first-episode psychotic patients who were neuroleptic-naive were studied to examine predictors of acute dystonia after treatment with haloperidol." | 5.07 | Predictors of acute dystonia in first-episode psychotic patients. ( Aguilar, EJ; Gómez-Beneyto, M; Hernández, J; Keshavan, MS; Martínez-Quiles, MD; Schooler, NR, 1994) |
| " Dosage was chosen and adjusted to the individual patient's condition and response." | 2.67 | Zuclopenthixol and haloperidol in patients with acute psychotic states. A double-blind, multi-centre study. ( Eliander, H; Heikkilä, L; Pedersen, V; Turunen, M; Vartiainen, H, 1992) |
| "Aripiprazole is a new generation antipsychotic drug with a partial agonist effect on dopamine D2 and D3 receptors." | 1.35 | Aripiprazole in combination with other antipsychotic drugs may worsen psychosis. ( Adan-Manes, J; Garcia-Parajua, P, 2009) |
| " There were no significant metabolic or organic cerebral changes that could have accounted for the symptoms which presumably had been induced by the drugs even though their dosage was not unusual." | 1.29 | [Drug-induced asterixis]. ( Leblhuber, F; Rittmannsberger, H, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (52.38) | 18.7374 |
| 1990's | 4 (19.05) | 18.2507 |
| 2000's | 2 (9.52) | 29.6817 |
| 2010's | 4 (19.05) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Vingerhoets, C | 2 |
| Bakker, G | 2 |
| van Dijk, J | 1 |
| Bloemen, OJN | 2 |
| Wang, Y | 1 |
| Chan, RCK | 1 |
| Booij, J | 2 |
| van Amelsvoort, TAMJ | 2 |
| Escobar-Vidarte, MF | 1 |
| Loaiza-Osorio, S | 1 |
| Messa, AA | 1 |
| Macías, GE | 1 |
| Schrantee, A | 1 |
| van der Pluijm, M | 1 |
| Reneman, L | 1 |
| Caan, M | 1 |
| Adan-Manes, J | 1 |
| Garcia-Parajua, P | 1 |
| Varol Tas, F | 1 |
| Guvenir, T | 1 |
| Grootens, KP | 1 |
| van Veelen, NM | 1 |
| Peuskens, J | 1 |
| Sabbe, BG | 1 |
| Thys, E | 1 |
| Buitelaar, JK | 1 |
| Verkes, RJ | 1 |
| Kahn, RS | 1 |
| STEINBRECHER, W | 1 |
| MATIAR-VAHAR, H | 1 |
| Friis, T | 1 |
| Christensen, TR | 1 |
| Gerlach, J | 2 |
| Aguilar, EJ | 1 |
| Keshavan, MS | 1 |
| Martínez-Quiles, MD | 1 |
| Hernández, J | 1 |
| Gómez-Beneyto, M | 1 |
| Schooler, NR | 1 |
| Meut, C | 1 |
| Bavoux, F | 1 |
| Cynober, E | 1 |
| Lebrun, F | 1 |
| Rittmannsberger, H | 1 |
| Leblhuber, F | 1 |
| Simmelsgaard, H | 1 |
| Fruensgaard, K | 1 |
| Korsgaard, S | 1 |
| Jorgensen, H | 1 |
| Jensen, K | 1 |
| Yaryura-Tobias, JA | 1 |
| Fledel, T | 1 |
| Neziroglu, F | 1 |
| Heikkilä, L | 1 |
| Eliander, H | 1 |
| Vartiainen, H | 1 |
| Turunen, M | 1 |
| Pedersen, V | 1 |
| Kuniyoshi, M | 1 |
| Inanaga, K | 1 |
| Kammerer, T | 1 |
| Schweitzer-Bucher, E | 1 |
| Jamet, P | 1 |
| Royer, M | 1 |
| Orlov, P | 1 |
| Kasparian, G | 1 |
| DiMascio, A | 1 |
| Cole, JO | 1 |
| Meyer, HH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Double-Blind, Randomized Trial Of Ziprasidone (80 - 160 Mg) Versus Olanzapine (10 - 20 Mg) In Patients With Recent-Onset Schizophrenia, Schizoaffective And Schizophreniform Disorder.[NCT00145444] | Phase 3 | 100 participants | Interventional | 2003-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for biperiden and Psychotic Disorders
| Article | Year |
|---|---|
Neuroleptic malignant syndrome in pregnancy: case report and literature review.
Topics: Anticonvulsants; Antipsychotic Agents; Biperiden; Female; Humans; Levetiracetam; Neuroleptic Maligna | 2019 |
7 trials available for biperiden and Psychotic Disorders
| Article | Year |
|---|---|
Influence of muscarinic M
Topics: Adult; Biperiden; Brain; Choline; Cognition; Corpus Striatum; Cross-Over Studies; Female; Gyrus Cing | 2019 |
Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial.
Topics: Adult; Alanine Transaminase; Antipsychotic Agents; Aspartate Aminotransferases; Basal Ganglia Diseas | 2011 |
Predictors of acute dystonia in first-episode psychotic patients.
Topics: Adolescent; Adult; Age Factors; Biperiden; Delusions; Double-Blind Method; Dystonia; Female; Haloper | 1994 |
Tardive dyskinesia during and following treatment with haloperidol, haloperidol + biperiden, thioridazine, and clozapine.
Topics: Aged; Biperiden; Clinical Trials as Topic; Clozapine; Dibenzazepines; Drug Therapy, Combination; Dys | 1978 |
Loxapine versus haloperidol parenterally in acute psychosis with agitation. A double-blind study.
Topics: Acute Disease; Adult; Aged; Aggression; Biperiden; Clinical Trials as Topic; Dibenzoxazepines; Doubl | 1977 |
Zuclopenthixol and haloperidol in patients with acute psychotic states. A double-blind, multi-centre study.
Topics: Adult; Aged; Biperiden; Clopenthixol; Double-Blind Method; Drug Administration Schedule; Drug Therap | 1992 |
Effect of different neuroleptics in tardive dyskinesia and parkinsonism. A video-controlled multicenter study with chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden. Nordic Dyskinesia Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Biperiden; Chlorprothixene; Dyskinesia, Drug-I | 1986 |
13 other studies available for biperiden and Psychotic Disorders
| Article | Year |
|---|---|
The effect of the muscarinic M
Topics: Administration, Oral; Adult; Biperiden; Cognition; Cross-Over Studies; Female; Humans; Learning; Mal | 2017 |
Aripiprazole in combination with other antipsychotic drugs may worsen psychosis.
Topics: Amisulpride; Anti-Dyskinesia Agents; Antipsychotic Agents; Aripiprazole; Biperiden; Dopamine; Drug T | 2009 |
Amisulpride treatment of adolescent patients with schizophrenia or schizo-affective disorders.
Topics: Adolescent; Amisulpride; Antiparkinson Agents; Antipsychotic Agents; Biperiden; Dose-Response Relati | 2009 |
[Akineton psychoses].
Topics: Biperiden; Cardiovascular Agents; Mental Disorders; Muscle Relaxants, Central; Parkinson Disease; Ps | 1958 |
[On an akineton induced psychosis with schizophrenic features].
Topics: Biperiden; Humans; Mental Disorders; Parasympatholytics; Psychoses, Substance-Induced; Psychotic Dis | 1961 |
Sodium valproate and biperiden in neuroleptic-induced akathisia, parkinsonism and hyperkinesia. A double-blind cross-over study with placebo.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Biperiden; Double-Blind Method; Drug Therapy, Combina | 1983 |
Necrotizing enterocolitis in a newborn: maternal psychotropic drugs suspected.
Topics: Adult; Biperiden; Chlorpromazine; Drug Therapy, Combination; Enterocolitis, Pseudomembranous; Female | 1994 |
[Drug-induced asterixis].
Topics: Biperiden; Clopenthixol; Clozapine; Drug Therapy, Combination; Electromyography; Female; Humans; Lit | 1994 |
Vitamins, neuroleptics, and antiparkinsonian drugs in catecholamine excretion.
Topics: Adult; Antiparkinson Agents; Biperiden; Chlorpromazine; Dopamine; Epinephrine; Humans; Male; Nicotin | 1976 |
Haloperidol and biperiden plasma levels in a pregnant atypical psychotic woman and a neonate--a case report.
Topics: Adult; Biperiden; Female; Haloperidol; Humans; Infant, Newborn; Male; Maternal-Fetal Exchange; Milk, | 1985 |
[Study of the delayed-action form of a synthetic antiparkinsonian drug: Akineton].
Topics: 1-Propanol; Adolescent; Adult; Antiparkinson Agents; Basal Ganglia Diseases; Biperiden; Catatonia; D | 1972 |
Withdrawal of antiparkinson drugs.
Topics: Biperiden; Butyrophenones; Female; Humans; Male; Parasympatholytics; Parkinson Disease; Psychotic Di | 1971 |
[On the question of possible irreversible disorders due to psychopharmacotherapy].
Topics: Adult; Autonomic Nervous System; Biperiden; Butyrophenones; Central Nervous System; Chlorpromazine; | 1966 |